Company Projected Revenue: fsdpharma.com (HUGE)

FSD Pharma (HUGE) - corporate logo

On GURU.Markets, the product sales volume forecast demonstrates a trend where the value of 0.00 aligns with the current metric. Risks for FSD Pharma Inc. (HUGE) are increasing due to a capital shortage and a lack of approved drugs. Unstable leadership strategies and share dilution are eroding confidence in management. However, patents for synthetic cannabinoids create venture potential that requires long-term R&D funding.

Company Expected Sales Volume: FSD Pharma, Inc. (HUGE) for 07/04/2022 - 08/15/2024

Summary analytical data breakdowns for FSD Pharma Inc. (HUGE)

- stock value and consensus price forecast:
Price Chart FSD Pharma, Inc.|HUGE - Average Forecast Price
- company stock exchange capitalization indicators:
Market Value FSD Pharma Inc.|HUGE - Total Company Value
- balance sheet equity data:
Net Assets per Single Share FSD Pharma|HUGE - Total Stockholders' Equity|Market Capitalization to Book Value Ratio fsdpharma.com|HUGE - Company Balance Sheet Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio FSD Pharma Inc.|HUGE - Long-Term Liabilities to Capital|Short-Term Debt to Capital FSD Pharma|HUGE - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio FSD Pharma Inc.|HUGE - Long-Term Debt Volume|Company Short-Term Debts FSD Pharma|Quick Liquidity Indicator fsdpharma.com
- company profitability and valuation multiples indicators:
HUGE - Final Profit|Expected Profit FSD Pharma Inc.|HUGE - Market Cap to Net Income|Forward P/E Multiple FSD Pharma|HUGE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple FSD Pharma|HUGE - Operating profit EBITDA|Earnings per share for the last twelve months FSD Pharma|HUGE - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months fsdpharma.com|HUGE - Net earnings per share growth this year|Earnings growth forecast for next year FSD Pharma Inc.
- sales and revenue data:
HUGE - Revenue and Sales Volume|Company Future Sales Volume FSD Pharma Inc.|HUGE - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple FSD Pharma Inc.|HUGE - Annual Revenue Growth (Last Twelve Months)
Fundamental company valuation:HUGE FSD Pharma, Inc.
Product sample of FSD Pharma, Inc.

The specifics of the sovereign cycle of FSD Pharma Inc. (HUGE) make this indicator a key filter for assessing revenue stability. This metric eliminates market noise and price anomalies, revealing the true fundamental potential of product realization. By analyzing the company's target sales dynamics, an investor sees forecasts stripped of emotional volatility. Peaks signal overvaluation, while dips indicate the asset is undervalued. Stable demand for innovation confirms the issuer's defensive profile.

Main competitors

Company Projected Revenue Jazz Pharmaceuticals Corp (JAZZ)|CYTK - Company Expected Sales Volume|Company Projected Revenue PTC Therapeutics Corp PTCT|Scholar Rock Inc. - Company Projected Revenue|CNTA - Company Projected Revenue|Company Sales Forecast Dyne Therapeutics (DYN)|EWTX: Projected Sales Volume|Company Sales Forecast Rapport Pharma RAPP|Company Future Sales Volume ALMS|Company Expected Sales Volume Zevra Therapeutics ZVRA|Projected Sales Volume CTNM|Company Projected Revenue LRMR (Larimar Therapeutics)|Projected Sales Volume CAPR (Capricor Therapeutics Inc.)|TRDA: Company Revenue Forecast|Channel Therapeutics Inc. - Projected Sales Volume|MNOV (medicinova.com) - Company Revenue Forecast|Serina Therapeutics (SER) - Company Projected Revenue|Company Revenue Forecast BTAI|Company Projected Revenue ProMIS Neurosciences, Inc.|Company Expected Sales Volume Apimeds Pharmaceuticals APUS|Projected Sales Volume AEON|NLSP (NLS Pharmaceutics) - Company Future Revenue|Projected Sales Volume BNOX (bionomics.com.au)|RETA (Reata Pharmaceuticals) - Company Expected Revenue